FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD
Facultad
University of Erlangen-Nuremberg
Erlangen, AlemaniaPublicaciones en colaboración con investigadores/as de University of Erlangen-Nuremberg (3)
2017
2016
-
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366
-
Clinical delineation of the PACS1-related syndrome-Report on 19 patients
American Journal of Medical Genetics, Part A, Vol. 170, Núm. 3, pp. 670-675